Providing automated, in-house and on demand oligonucleotide production in only a few hours, the SYNTAX platform will be distributed across Latin American by Gencell and in South Korea by BMS, with customers in Japan to be supported by Biostream.
Each of the companies distributing SYNTAX will provide local access to DNA synthesis without a reliance on overseas manufacturing, through established regional networks, shifting the current centralised supply chains to local DNA production.
Iwabuchi Takeshi, President of BioStream, said: “This partnership strengthens our ability to deliver advanced life sciences technologies throughout Japan, helping customers reduce dependence on overseas synthesis and long delivery timelines.”
While oligonucleotides are a critical input for a wide range of applications, researchers who are located far away from large-scale synthesis centres can experience long delivery times or logistical constraints, leading to project delays.
Dukhyun Lim, Vice President of Bio-Medical Science, BMS, said: “SYNTAX offers researchers greater control and speed in oligonucleotide production, enabling increased independence and control over project workflows, and we are pleased to support its availability in South Korea.”
The aim of the expansion is to broaden the global use of SYNTAX to allow researchers who are far from the oligonucleotide production hubs in Europe and the US to access DNA faster and more reliably.
Fabio Andrés Zapata, CEO of Gencell, said: “We are proud to strengthen the region’s scientific and technological capabilities, positioning Latin America as an increasingly competitive player in global science and biotechnology.”
DNA Script is focused on improving DNA accessibility in the future, through its proprietary Enzymatic DNA Synthesis (EDS) technology, which is provided in an automated, benchtop system in SYNTAX.
Marc Montserrat, Chief Executive Officer, DNA Script, said: “These new partnerships [are] part of our strategy to scale global accessibility and availability of ssDNA oligos, making them available to researchers anywhere in the world.”
